Recent Finacing
Recent Raise
Septerna uses a Native Complex™ Platform to recapitulate native GPCR structure and dynamics ex vivo, enabling industrial-scale small-molecule screening and structure-based design; lead program is an oral PTH1R agonist.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Septerna.
